Abstract
To date, most treatment decisions for adjuvant chemotherapy in breast cancer are based on conventional clinicopathological criteria. Since breast cancer tumors with similar clinicopathological characteristics can have strikingly different outcomes, the current selection for adjuvant chemotherapy is far from accurate. Using high-throughput microarray analysis, a 70-gene signature was identified which can accurately select early stage breast cancer patients who are highly likely to develop distant metastases, and therefore, may benefit the most from adjuvant chemotherapy. This review describes the development of the 70-gene profile (Mammaprint®™), its retrospective validation and feasibility studies, and its prospective validation in the large adjuvant MINDACT (Microarray In Node-negative Disease may Avoid ChemoTherapy) clinical trial.
- Breast cancer
- prognostic
- chemotherapy
- gene expression microarray
- 70-gene profile
- Mammaprint®™
- validation
- MINDACT
- review
Footnotes
- Received March 8, 2007.
- Revision received April 25, 2007.
- Accepted April 26, 2007.
- Copyright © 2007 The Author(s). Published by the International Institute of Anticancer Research.
In this issue
Jump to section
Related Articles
Cited By...
- Machine learning investigation of gene expression datasets reveals TP53 mutant-like AML with wild type TP53 and poor prognosis
- Pathway-Structured Predictive Model for Cancer Survival Prediction: A Two-Stage Approach
- A Comparison of the Performance of EndoPredict Clinical and NHS PREDICT in 120 Patients Treated for ER-positive Breast Cancer
- Pathway-Structured Predictive Model for Cancer Survival Prediction: A Two-Stage Approach
- Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX(R)) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early-Stage Estrogen Receptor-Positive Breast Cancer
- Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges